The June vaccine advisory agenda was cut in half two days before the meeting

Federal advisory committees announce their business in advance, in the Federal Register, and the notice is a legal document rather than a press release. That makes the paper trail around the Advisory Committee on Immunization Practices meeting of 25-27 June unusually legible — and unusually striking, because the agenda published on 9 June and the amended agenda published on 24 June are not the same agenda.

What was announced on 9 June

The original notice, filed 6 June and published 9 June under Docket No. CDC-2025-0024, set the meeting for three days: 25 June from 8 a.m. to 5 p.m. EDT, 26 June from 8 a.m. to 5 p.m., and 27 June from 8 a.m. to 3 p.m. [s1].

The listed matters to be considered were anthrax vaccines, chikungunya vaccines, COVID-19 vaccines, cytomegalovirus vaccine, human papillomavirus vaccine, influenza vaccines, Lyme disease vaccine, meningococcal vaccines, pneumococcal vaccines, respiratory syncytial virus vaccines for adults, and RSV vaccines for maternal and paediatric populations — eleven topics [s1].

Recommendation votes were scheduled for six of them: COVID-19 vaccines, HPV vaccine, influenza vaccines, meningococcal vaccine, RSV vaccines for adults, and RSV vaccine for maternal and paediatric populations [s1]. Separate Vaccines for Children programme votes were scheduled for COVID-19 vaccines, HPV vaccine, influenza vaccines and RSV vaccines [s1]. The written comment docket was to be open from 9 to 20 June, and requests to give oral comment were due by 11:59 p.m. on 20 June, with each speaker limited to three minutes [s1].

What was announced on 24 June

The amended notice, filed 23 June and published 24 June, changed both the schedule and the substance [s2].

The meeting was cut to two days: 25 June from 10 a.m. to 5:30 p.m. EDT and 26 June from 8 a.m. to 1 p.m. [s2]. By the arithmetic of the notices themselves, that is a reduction from roughly 25 scheduled hours to roughly 12.5.

The matters to be considered were restated as anthrax vaccines, chikungunya vaccines, COVID-19 vaccines, influenza vaccines, measles, mumps, rubella and varicella (MMRV) vaccine, RSV vaccines for maternal and paediatric populations, and an update on work groups [s2]. Cytomegalovirus, HPV, Lyme disease, meningococcal, pneumococcal and adult RSV vaccines are no longer listed; MMRV vaccine, which did not appear on the 9 June agenda, is [s2].

Recommendation votes were reduced to two — influenza vaccines and RSV vaccine for maternal and paediatric populations — with a single Vaccines for Children vote, on RSV vaccines [s2]. The COVID-19, HPV and meningococcal votes listed on 9 June do not appear in the amended list [s2].

Why the agenda is not a trivial document

The notice explains the committee's statutory position, and it is worth quoting the mechanism rather than the politics. Under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review the list of vaccines administered to eligible children through the Vaccines for Children programme, along with dosing intervals, dosage and contraindications [s1]. Under provisions of the Affordable Care Act and section 2713 of the Public Health Service Act, committee recommendations that are adopted by the CDC director and appear on the CDC immunization schedules generally must be covered by applicable health plans [s1].

In other words, an item that moves from "vote scheduled" to "not on the agenda" is not only a scientific deferral. It is a deferral of the step that connects a recommendation to paediatric vaccine supply and to insurance coverage.

The two notices state what changed. They do not state why, and this article asserts nothing about the reason, the deliberations or any outcome. Neither notice reports a vote result; both were published before or during the meeting itself.

The wider record from the same weeks

The committee's ordinary output continued to appear in the meantime. On 19 June, MMWR published the committee's recommendations for use of JYNNEOS, the live, non-replicating smallpox and mpox vaccine, in people aged 18 and over at risk during an mpox outbreak — recommendations dated to 2023 and formally published two years later [s3]. That publication lag is itself a reminder that the committee's paperwork and the committee's meetings run on different clocks.

The composition and independence of the committee also became a subject in the peer-reviewed literature during the same week. On 24 June, Annals of Internal Medicine published a commentary titled "Preserving Scientific Integrity in Vaccine Policy: The Role of, and Risk to, the CDC's Advisory Committee on Immunization Practices" [s4]. We cite it here for what is verifiable from the publication record — that the question was being raised in a general medical journal at the same time the agenda was being rewritten — and not for its arguments, which sit behind a paywall we could not read.

What to watch

Whether the deferred items — CMV, HPV, Lyme, meningococcal, pneumococcal and adult RSV vaccines — reappear on a later Federal Register notice, and whether the votes that were dropped from the June agenda are rescheduled or dropped altogether [s1][s2]. The Federal Register is the place that answer will show up first, and it will show up as an agenda before it shows up as a decision.

Sources

• [s1] Meeting of the Advisory Committee on Immunization Practices (Docket No. CDC-2025-0024). Federal Register, Vol. 90, No. 109, pp. 24278-24279, 9 June 2025. https://www.federalregister.gov/documents/2025/06/09/2025-10432/meeting-of-the-advisory-committee-on-immunization-practices
• [s2] Meeting of the Advisory Committee on Immunization Practices; Amended Notice of Meeting. Federal Register, Vol. 90, No. 119, p. 26817, 24 June 2025. https://www.federalregister.gov/documents/2025/06/24/2025-11567/meeting-of-the-advisory-committee-on-immunization-practices-amended-notice-of-meeting
• [s3] Use of JYNNEOS for Persons Aged ≥18 Years at Risk for Mpox During an Mpox Outbreak: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR, 19 June 2025. https://doi.org/10.15585/mmwr.mm7422a3
• [s4] Preserving Scientific Integrity in Vaccine Policy: The Role of, and Risk to, the CDC's Advisory Committee on Immunization Practices. Annals of Internal Medicine, 24 June 2025. https://doi.org/10.7326/ANNALS-25-02806